Table 3.
Changing in biological blood parameters during the test period
| 0 month (baseline§) |
6 months (treatment) |
9 months (follow-up) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo (n = 23) | PS100 (n = 25) | PS300 (n = 25) | Placebo (n = 23) | PS100 (n = 25) | PS300 (n = 25) | Placebo (n = 23) | PS100 (n = 25) | PS300 (n = 25) | |
| AST (units/L) | 25.3 (15.3) | 24.0 (6.6) | 22.2 (9.3) | 26.1 (18.7) | 23.2 (6.6) | 22.8 (7.5) | 24.0 (14.6) | 21.6 (5.1) | 21.2 (8.5) |
| ALT (units/L) | 30.7 (31.2) | 24.7 (15.6) | 23.0 (14.0) | 26.7 (26.1) | 20.2 (8.0) | 23.3 (13.3) | 26.2 (24.5) | 22.2 (8.9) | 22.1 (11.7) |
| Alkaline phosphatase (units/L) | 225.7 (56.0) | 212.8 (51.8) | 230.1 (45.7) | 228.3 (61.2) | 220.6 (53.5) | 214.2 (41.2) | 220.2 (60.1) | 218.7 (47.1) | 215.4 (45.1) |
| Lactose dehydrogenase (units/L) | 191.7 (39.6) | 197.5 (37.0) | 187.2 (23.7) | 187.4 (40.9) | 183.9 (24.7) | 180.6 (26.0) | 191.5 (41.9) | 193.1 (25.6) | 189.1 (18.9) |
| γ-GTP (units/L) | 33.9 (17.8) | 29.7 (17.5) | 34.9 (30.6) | 32.4 (21.1) | 27.8 (19.8) | 32.8 (31.4) | 30.6 (18.9) | 27.9 (18.0) | 30.8 (27.8) |
| Creatine phosphokinase (units/L) | 121.6 (54.8) | 166.3 (115.1) | 115.3 (57.5) | 125.1 (41.4) | 149.8 (114.1) | 116.5 (56.4) | 128.2 (55.9) | 175.0 (153.7) | 113.5 (45.7) |
| Creatinine (mg/dL) | 0.7 (0.1) | 0.8 (0.2) | 0.7 (0.2) | 0.7 (0.1) | 0.7 (0.2) | 0.7 (0.2) | 0.7 (0.1) | 0.8 (0.1) | 0.7 (0.2) |
| Blood urea nitrogen (mg/dL) | 14.9 (2.9) | 14.7 (3.6) | 14.5 (2.6) | 15.3 (3.4) | 15.1 (4.1) | 14.3 (2.8) | 15.7 (3.7) | 15.9 (3.7) | 15.6 (3.1) |
| Uric acid (mg/dL) | 5.2 (1.3) | 5.7 (1.4) | 4.9 (1.3) | 5.3 (1.5) | 5.5 (1.4) | 5.1 (1.4) | 5.2 (1.4) | 5.6 (1.5) | 4.9 (1.4) |
| HDL-cholesterol (mg/dL) | 65.5 (14.7) | 71.9 (14.7) | 65.1 (14.8) | 65.2 (15.3) | 72.1 (14.6) | 65.1 (11.5) | 63.3 (16.1) | 69.3 (13.6) | 63.2 (13.5) |
| LDL-cholesterol (mg/dL) | 141.0 (38.2) | 128.3 (25.9) | 134.3 (34.7) | 130.5 (29.1) | 127.7 (25.4) | 142.3 (36.9) | 130.9 (31.6) | 126.3 (28.7) | 134.2 (31.9) |
| Triglyceride (mg/dL) | 111.9 (60.8) | 89.6 (34.8) | 116.1 (63.6) | 121.6 (92.0) | 104.7 (56.5) | 113.0 (48.0) | 124.0 (103.7) | 99.8 (35.5) | 125.7 (73.9) |
| Blood glucose (mg/dL) | 91.3 (10.7) | 86.2 (10.8) | 87.5 (6.1) | 94.7 (13.3) | 86.9 (7.5)# | 89.6 (8.7) | 94.4 (11.3) | 91.5 (9.4) | 93.2 (11.0) |
Values are means (standard deviation). §The values at screening were used as baseline values. Subjects started taking the samples within one month after screening. The follow-up period consisted of 3 months after finishing the 6 months of sample intake, during which subjects took no sample. #p<0.05 vs placebo group (Dunnett’s multi-comparison test). AST; Asparate amino transferase, ALT; Alanine transaminase.